GoldenGolden
Advanced Search
Veralox Therapeutics

Veralox Therapeutics

Veralox Therapeutics is a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc.

Veralox Therapeutics is a small molecule drug discovery and development company that is developing small molecule therapeutics for the purpose of treating the underlying pathologies of thrombosis and type 1 diabetes. Based on the understanding of the molecular mechanisms of the diseases, the efforts will turn to new treatment ways and better patients' outcomes.

Veralox is developing a disease-modifying therapy for Type 1 diabetes, another immune-driven pathology. In Type 1 diabetes patients, an abnormal immune response results in damage and destruction to insulin-producing pancreatic β-cells, inflammatory signals increase the expression of 12-LOX, leading to an overabundance of 12-HETE. 12-HETE stresses β-cells leading to a reduction in insulin production, by inhibiting 12-LOX in the pancreas and shutting down production of 12-HETE, insulin β-cells are preserved and able to function properly.

With a high number of T1D patients, particularly new-onset T1D patients having functional β-cells, the approach of Velarox is promising to sustain insulin production in these patients.

Timeline

June 16, 2021
Veralox Therapeutics raises a $16,600,000 series A round.
September 2019
Veralox Therapeutics raises a $5,400,000 seed round from JDRF T1D Fund, Maryland Momentum Fund, Sanofi Ventures, University of Vermont Health Network, VTC Seed Fund and Virginia Tech Carilion (VTC) Innovation Fund.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.